Cita APA

Matulonis, U. A., Walder, L., Nøttrup, T. J., Bessette, P., Mahner, S., Gil-Martín, M., . . . Mirza, M. R. (2019). Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: A TWiST analysis of the ENGOT-OV16/NOVA trial.

Citación estilo Chicago

Matulonis, Ursula A., et al. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. 2019.

Cita MLA

Matulonis, Ursula A., et al. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. 2019.